fluoropyrimidine, HER2-tabbatacce, oxaliplatin, Seagen Inc., tucatinib, Tukysa
An ba da izini ga gaggawa ta FDA zuwa tucatinib tare da trastuzumab don ciwon daji na launi
A cikin Fabrairu 2023, Hukumar Abinci da Magunguna (FDA) ta haɓaka amincewar tucatinib (Tukisa, Seagen Inc.) da trastuzumab don kula da RAS daji mai nau'in HER2 mai cutar kansa wanda ya yaɗu ko kuma ba zai iya zama rem ba.
fluoropyrimidine, Ciwon mahaifa (GEJ) adenocarcinoma, KEYTRUDA, Merck & Co., Pembrolizumab, Trastuzumab
Pembrolizumab tana samun amincewar gaggawa daga FDA don cutar kansa ta ciki HER2
Agusta 2021: Pembrolizumab (Keytruda, Merck & Co.) a haɗe tare da trastuzumab, fluoropyrimidine-, da platinum-dauke da chemotherapy an ba da izini cikin hanzari ta Hukumar Abinci da Magunguna don firs.
Bristol Myers Squibb, Farashin-649, fluoropyrimidine, nivolumab, Abin al'ajabi, platinum-dauke da chemotherapy
Nivolumab ban da chemotherapy FDA ta amince da ita don ciwon daji na ciki na ciki da adenocarcinoma esophageal
Agusta 2021: Don ci gaba ko ciwon daji na ciki na ciki, ciwon daji na mahaifa na gastroesophageal, da adenocarcinoma esophageal, Hukumar Abinci da Magunguna ta amince da nivolumab (Opdivo, Kamfanin Bristol-Myers Squibb) a cikin haɗin gwiwa.